Advances in nanotechnology have had significant impacts on the field of biodiagnostics. In this study, we describe the novel application of dissolvable, organic, and biofunctional nanocrystals for the quantitative detection of a PCR product. 
Introduction
Human papillomavirus (HPV) is a relatively small, non-enveloped virus, 55 nm in diameter, with a circular genome [1] . HPV is one of the most common sexually transmitted infections (STIs) and is considered to be a major cause of cervical cancer [2, 3] . Cervical cancer has the second highest mortality rate (after breast cancer) among female patients worldwide [4] . Annually, about 240,000 women worldwide die from cervical cancer, accounting for 10% of all cancer-related deaths in women [5] .
Over 100 HPV genotypes have been identified, some 40 of which are known to infect the ano-genital tract, and are thus closely related to cervical cancer [1, 4, [6] [7] [8] .
Based on their potential to induce cervical cancer and preneoplastic lesions of cervical intraepithelial neoplasia, HPV genotypes can be classified into high-risk (HR) and low-risk (LR)-HPV groups. HR-HPV genotypes are found in the majority of cervical cancer patients [1, 4, 6] . Infection with high-risk genotypes HPV 16, HPV 18 and HPV 45 accounts for almost 80% of all squamous cervical carcinomas worldwide [5, 9, 10] .
Cytology and histology are the conventional diagnostic tools for cervical cancer.
The detection of HPV-DNA offers an alternative or complement to the regular cytological screening of cervical cancer. Various HPV-DNA detection methods have been developed based on DNA amplification using either Polymerase Chain Reaction (PCR) techniques and/or liquid hybridization [1, 11] . PCR techniques to amplify HPV 4 gene fragments are now used in routine HPV diagnostics [12] . Most studies on HPV-DNA employ consensus primers for the amplification of the L1 open reading frame region in order to cover a broad spectrum of HPV genotypes [13] . The amplified HPV-DNA is identified by sequencing or hybridization with a specific sequence of a DNA or RNA probe. The hybridized DNA-DNA or DNA-RNA complex is then detected by means of colorimetric or chemiluminence techniques [2, 14] .
Advances in nanotechnology have had significant impacts on the field of biodiagnostics [15] [16] [17] . In a previous study, we applied a novel signal amplification technology based on a new class of biofunctional fluorogenic nanocrystals to improve the sensitivity and the limits of detection in immunoassays [18] [19] [20] [21] . A simple two-step approach was used to encapsulate nanocrystalline fluorescein diacetate (FDA) with an average size of 107 nm with ultrathin polyelectrolytic distearoylphosphatidylethanolamine (DSPE) lipids coupled with amino(poly(ethylene glycol)) (PEG2000-Amine) [19] . This polyelectrolyte coating was subsequently used as an interface for the attachment of biorecognition molecules through adsorption biolabels could be stored as a highly stable colloidal suspension, which resulted in minimal nonspecific interactions. The limit of detection was lowered by a factor of 5 to 28 and the sensitivity was 400 to 2700-fold higher compared with a state-of-the-art immunoassay using directly fluorescent-labeled antibodies. In addition, the applicability of NeutrAvidin-labeled nanocrystals was demonstrated in an immunoassay [20] . The limit of detection was lowered by a factor of 2.5 to 21 and the sensitivity was 3.5 to 30-fold higher than immunoassays using commercial labeling systems [i.e. fluorescein 5-isothiocyanate (FITC) and horseradish peroxidase (HRP)].
The biofunctional nanocrystals were also applied to detect different kinds of clinically interesting plasma proteins with high sensitivity, low limits of detection and short incubation times [21] . These results suggested that these functionalized FDA nanoparticles would be useful in the detection of nucleic acids as the final step in PCR-based tests.
In this study, a set of consensus primers, 5' biotinylated PGMY09/11 [22] , was used to amplify HPV-DNA from various concentrations of HPV 16, HPV 18 and HPV 45 plasmids. Biotinlyated HPV-DNA was amplified and hybridized specifically with DNA probes that had been immobilized on a NucleoLink TM microplate (Scheme 2).
The biotin molecule of the specific hybridized HPV-DNA was finally coupled with streptavidin that had been conjugated with FDA nanocrystals. The performance of the 6 nanocrystal biolabel system was then compared with various directly labeled systems (i.e., FITC and peroxidase).
Experimental

Materials
Fluorescein diacetate ( 
Instrumentation
An fmax Fluorescence Microplate Reader and a SPECTRAmax 340PC Microplate
Reader were purchased from Molecular Devices Corporation (Sunnyvale, CA) for measurements of fluorescence intensity and absorbance respectively. The pretreated particle suspension was diluted to 0.0626% (w/v) and incubated with 200 µg/mL streptavidin in 10 mM phosphate-buffered saline (PBS, pH 7.4) at room temperature for 1 h. The supernatant was removed after centrifugation at 16,000g for 10 min. After three repeated centrifugation/washing cycles, the streptavidin-coated particles were finally separated from the streptavidin solution. The plates were stored in ethylene bags at 4ºC until use. for 45 s, 65ºC for 30 s. This was followed by a final extension at 65ºC to 5 min. The 9 amplification reaction mixtures were examined by gel electrophoresis in 1.5% agarose gel with ethidium bromide staining and stored at 4ºC.
Immobilization of DNA probes in microplate
HPV-DNA amplification
Amplified HPV-DNA hybridization
Amplified HPV-DNA, labeled with biotin during the amplification reaction, was 
Results and discussion
Application of Nanocrystalline FDA Biolabels in DNA Hybridization Assays
The assays were conducted in 96-well microtitre plates utilizing internal primers labeled with biotin. The amplicons were hybridized with the immobilized HPV 16, 18 or 45 probes and detected using FDA/FITC/HRP-labeled streptavidin. Figure 1 shows the calibration curves of the assays performed with the streptavidin-FDA nanocrystal labels. The fluorescence signal is directly proportional to the amplicon concentration in the range of 10 3 to10 5 copies/µL (Figure 1 ). To minimize nonspecific binding, low concentrations of the fluorescent-labeled streptavidin conjugate are typically preferred.
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No increase in the signal intensity was registered in our assays with increasing concentrations of unmatched amplicons hybridized with the immobilized HPV probes up to 10 5 copies/µL (Figure 1 ).
Comparison of Nanocrystalline FDA-Labeled Streptavidin with Commercially Available Directly Labeled Streptavidins
The performance of the streptavidin-FDA nanocrystal label was compared with directly FITC-labeled and HRP-labeled streptavidin conjugates. Although the HRP system allowed ultra-sensitive detection of HPV-DNA (down to 100 copies/µl), the method did not provide quantitative information on the viral load. Neither did the FITC-labeled streptavidin conjugates. In contrast, the nanocrystalline FDA system did produce quantitative results without nonspecific interactions with the other probes ( Figure 1 ). Moreover, depending on the amplicon concentration and the HPV genotype, the FDA system yielded much higher S/N ratios (Table 1 ; absolute data shown in Table S -1) with a concomitant sensitivity enhancement by a factor of 2.8 to 147.0 compared with the directly FITC-labeled streptavidin ( Table 2 ).
The high sensitivity of the particle-based conjugates probably results from the boosting effect of the dissolving dye molecules, but the minimized quenching could also have contributed to the improved signal.
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As well as detecting HPV, it is also important to discriminate between HR and LR-HPV genotypes. The assay described above reliably detects 11 HR-HPV genotypes and yields the highest S/N ratios (Table 3 ; absolute data shown in Table   S-3) . We immobilized the 11 HR-HPV genotypes in a single well and hybridized them with different amplicons by using FDA/FITC/HRP-labeled streptavidin for detection.
The labeled amplicons and the FDA/FITC/HRP labeled streptavidin were added sequentially to coated microtitre plates to permit maximal binding. Compared with other reagents used to detect PCR products (e.g., ethidium bromide and radioisotopes),
FDA is non-hazardous and fast because there is no color processing. After addition of the releasing reagent, the instant fluorescence intensity is over 90% of the maximum and reaches the maximum within 5 minutes. On the other hand, common metal ions in human body have no interference with FDA. Furthermore, the fluorescence detection is performed in microtitre plates rather than in tubes, which permits rapid dispensing of reagents with multichannel pipetting equipment and the possibility of automation using robotic arms.
Conclusion
We have demonstrated a novel signal amplification technology for a HPV-DNA hybridization assay based on FDA nanocrystals encapsulated within 
